Integrated BioPharma amended its credit arrangements with PNC Bank, extending the maturity of its $4.0 million revolving credit facility to April 14, 2027, and establishing a new $250,000 Convertible Equipment Line of Credit for capital purchases. Concurrently, the company retired its previously matured $500,000 convertible equipment line, which has been replaced by the new facility. The updates are intended to maintain liquidity and provide targeted financing for equipment and vehicles.
Agreement 1: Integrated BioPharma Extends $4M Revolving Credit Line With PNC Bank to April 2027
- Agreement type: Amendment extending committed revolving credit facility
- Counterparty: PNC Bank
- Signed / Effective: Jun 30 2026 / same
- Duration / Termination: Through Apr 14 2027
- Reason: Extend liquidity under existing revolver
Agreement 2: Integrated BioPharma Establishes $250K Convertible Equipment Line of Credit With PNC Bank
- Agreement type: Convertible equipment line of credit note (Daily SOFR)
- Counterparty: PNC Bank
- Signed / Effective: Jun 30 2026 / same
- Reason: Finance equipment and vehicle purchases
Agreement 3: Integrated BioPharma Retires Matured $500K Convertible Equipment Line With PNC Bank
- Agreement terminated: Convertible equipment line of credit note (Daily SOFR)
- Counterparty: PNC Bank
- Original agreement date: Apr 15 2025
- Termination date: Jun 30 2026
- Termination type: expiry
- Exit fees / payments: None
- Reason: Matured and replaced by new Convertible ELOC
Original SEC Filing:
This is an AI-powered summary. It may contain inaccuracies. Consider verifying important information with the source. Please note this summary is solely based on documents filed with the SEC.